読み込み中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$29.36
−$1.16 · -3.80%
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
前日終値
$29.36
−$1.16 · -3.80%
日中の時刻はETです。市場データは遅延する場合があります。
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
日中レンジ
現在 $29.36
52週レンジ
現在 $29.36
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
79
割安
センチメント
69
強気
リスク
44
やや高いリスク
モメンタム
46
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
日中レンジ
現在 $29.36
52週レンジ
現在 $29.36
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$66.50
上昇余地（126.50%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3696.33万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2596.75万0.03%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1422.45万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO907.94万0.07%139.17億 USD0.24%$356.78+0.94%
Dimensional - US Small Cap ETFDFAS838.2万0.02%338.69億 USD0.31%$78.35+0.32%
State Street SPDR S&P Pharmaceuticals ETFXPH762.27万1.65%4.62億 USD0.35%$64.65+1.60%
Vanguard Russell 2000 ETFVTWO686.52万0.04%180億 USD0.06%$112.66+0.50%
Fidelity Enhanced Small Cap ETFFESM565.88万0.09%64.1億 USD0.28%$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
